Key result
PARP-1 inhibition significantly decreased right ventricular pressure and hypertrophy, and improved endothelial function in a rat model of pulmonary hypertension.
Why the study?
The role of PARP-1 in pulmonary arterial endothelial dysfunction associated with pulmonary hypertension had not been explored completely.
Does PARP-1 inhibition improve endothelial function in preclinical models of pulmonary hypertension?
Does PARP-1 inhibition improve endothelial function in preclinical models of pulmonary hypertension?
PARP-1 inhibition improves endothelial function and reduces right ventricular hypertrophy in preclinical models of pulmonary hypertension.
Answers are grounded in this paper and cite their sources.
PARP-1 inhibition may improve endothelial function in experimental PH; leaves open clinical translation and need for human trials.
Endothelial dysfunction is critical in the pulmonary vasculature during pulmonary hypertension (PH). Moreover, in PH, increased inflammation and oxidative/nitrosative stress cause DNA damage, activating poly (ADP-ribose) polymerase-1 (PARP-1). Meloche et al. (2014) and our previous research have shown that inhibiting PARP-1 is protective in PH and associated RV hypertrophy. However, the role of PARP-1 in pulmonary arterial endothelial dysfunction has not been explored completely. Therefore, the current study aims to investigate the involvement of PARP-1 in endothelial dysfunction associated with PH. Hypoxia (1% O2) was used to induce a PH-like phenotype in human pulmonary artery endothelial cells (HPAECs), and PARP-1 inhibition was achieved via siRNA (60 nM). For the in vivo study, male Sprague Dawley rats were administered monocrotaline (MCT; 60 mg/kg, SC, once) to induce PH, and 1, 5-isoquinolinediol (ISO; 3 mg/kg) was administered daily intraperitoneally to inhibit PARP-1. PARP-1 inhibition decreased proliferation and inflammation, as well as improved mitochondrial dysfunction in hypoxic HPAECs. Furthermore, PARP-1 inhibition also promoted apoptosis by increasing DNA damage in hypoxic HPAECs. In addition, inhibition of PARP-1 reduced cell migration, VEGF expression, and tubule formation in hypoxic HPAECs. In in vivo studies, PARP-1 inhibition by ISO significantly decreased the RVP and RVH as well as improved endothelial function by increasing the pulmonary vascular reactivity and expression of p-eNOS in MCT-treated rats.
No takes yet. Share an insight, caveat, or question.
Shafiq et al. (2023) studied Pulmonary hypertension. PARP-1 inhibition (siRNA or 1, 5-isoquinolinediol) vs. Hypoxia or monocrotaline alone was evaluated on Endothelial function, right ventricular pressure (RVP), and right ventricular hypertrophy (RVH). PARP-1 inhibition significantly decreased right ventricular pressure and hypertrophy, and improved endothelial function in a rat model of pulmonary hypertension.
Synapse has enriched 10 related papers. Consider them for comparative context: